When you buy through links on our articles, Future and its syndication partners may earn a commission.

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the ...

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics (“Orum”), a clinical-stage private biotechnology company pioneering Dual-Precision Targeted Protein Degradation (TPD² ™) and Targeted ...